{"filings":[{"id":2060356,"accession_number":"0001639691-26-000085","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2026-08-05T10:05:30+00:00","items":["2.02","9.01"],"status":"ready","headline":"LivaNova Q2 revenue up 10.8% to $390.6M; raises FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 GAAP diluted EPS $1.93; adjusted diluted EPS $1.26; revenue $390.6M (+10.8% reported, +9.8% constant currency).","Raised FY2026 constant-currency revenue growth guidance to 8%-9% (up 100 bps); adjusted EPS guidance raised to $4.30-$4.40 (midpoint +$0.10).","Lowered FY2026 adjusted free cash flow guidance to $140M-$160M; Q2 adjusted free cash flow $45.5M.","Recognized €81.8M ($95.4M) discrete tax benefit from favorable Italian tax authority ruling on SNIA environmental liability.","Entered long-term agreement with Thermo Fisher Scientific to increase oxygenator component supply and expand manufacturing output."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":983196,"accession_number":"0001639691-26-000053","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2026-06-11T13:07:43+00:00","items":["5.07","9.01"],"status":"ready","headline":"LivaNova shareholders approve all 10 proposals at 2026 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected with >99% support, including new members.","Advisory say-on-pay passed with 49.3M for vs 0.5M against.","PwC-U.S. ratified as auditor for 2026 with 51.2M for votes.","Share repurchase authority approved for up to 10% of outstanding shares.","UK directors' remuneration report and statutory accounts adopted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94306,"accession_number":"0001639691-26-000031","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LivaNova Q1 revenue $362.3M (+14.3% YoY); raises FY2026 guidance; FDA PMA for aura6000 OSA system","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $362.3M (+14.3% reported, +11.1% CC); GAAP EPS $0.40, adjusted EPS $0.98.","Raised FY2026 constant-currency revenue growth guidance to 7.0%-8.0% (up 100bps); adjusted EPS guidance raised to $4.20-$4.30.","Received FDA PMA for aura6000 HGNS system for moderate-to-severe OSA; no CCC contraindication or pre-implant DISE required.","Published 12-month OSPREY trial results in Annals of Internal Medicine; demonstrated clinically significant responses.","Q1 adjusted free cash flow $3.8M; maintained FY2026 adjusted FCF guidance $160M-$180M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":362258000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106564,"accession_number":"0001639691-26-000006","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LivaNova Q4 revenue $360.9M (+12.1%); FY25 adj. EPS $3.90; guides FY26 rev. growth 6-7%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP EPS $0.56; adjusted EPS $0.86. Full-year revenue $1.39B, +10.7% reported.","Full-year GAAP diluted loss per share $4.45 includes $365.6M SNIA environmental charge.","Full-year adjusted diluted EPS $3.90; adjusted free cash flow $183.3M.","2026 guidance: constant-currency revenue growth 6-7%; adjusted EPS $4.15-$4.25.","CMS increased reimbursement for VNS Therapy DRE procedures effective Jan 1, 2026; FDA approved cloud-based digital health platform."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":1388053000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106563,"accession_number":"0001639691-26-000002","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"LivaNova SVP, Chief Legal Officer Michael Hutchinson resigns effective Jan 26, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Hutchinson notified resignation on Jan 12, 2026 as SVP, Chief Legal Officer, and Company Secretary.","Resignation to pursue another opportunity; last day with LivaNova is January 26, 2026.","Company plans to retain external search firm to find a new Chief Legal Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122899,"accession_number":"0001639691-25-000146","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LivaNova Q3 revenue $357.8M (+12.5% organic); raises FY2025 EPS guidance to $3.80-$3.90","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Third-quarter revenue $357.8M, up 12.5% reported, 11% constant-currency, and 12.5% organic vs prior year.","GAAP diluted EPS $0.49; adjusted diluted EPS $1.11.","Raised FY2025 guidance: revenue growth 8.5%-9.5% constant currency, EPS $3.80-$3.90, FCF $160M-$180M.","Initiated commercial launch of Essenz Perfusion System in China, the second-largest heart-lung machine market.","Appointed Donald Zurbay to the Board of Directors and Audit and Compliance Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":1027132000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139598,"accession_number":"0001639691-25-000120","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LivaNova appoints Donald Zurbay to Board and Audit Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Donald Zurbay appointed to LivaNova Board and Audit & Compliance Committee effective September 4, 2025.","Zurbay most recently President & CEO of Patterson Companies (Oct 2022-May 2025); previously CFO at Patterson and St. Jude Medical.","Compensation: $70k annual retainer, $15k audit committee fee, $185k annual restricted stock award, prorated until 2026 AGM.","No material transactions or arrangements between Zurbay and LivaNova per Item 404(a) review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139597,"accession_number":"0001639691-25-000099","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LivaNova Q2 revenue $352.5M (+10.7%), raises FY25 adjusted EPS guidance to $3.70-$3.80","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $352.5M, +10.7% reported, +10.3% organic; GAAP EPS $0.50, adjusted EPS $1.05.","Raised FY25 guidance: revenue growth 8-9% constant-currency, adj. EPS $3.70-$3.80 (midpoint +$0.10).","Adj. free cash flow $47.8M; FY25 raised to $140-160M.","Initiated CMS reconsideration for VNS Therapy for treatment-resistant depression based on RECOVER study.","Published 24-month CORE-VNS data showing VNS reduces generalized tonic-clonic seizures in DRE."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":669379000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157180,"accession_number":"0001639691-25-000052","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"LivaNova shareholders approve 2.2M share increase in 2022 incentive plan and new director plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved Second Amended & Restated 2022 Incentive Award Plan, adding 2,200,000 shares for awards.","Also approved 2025 Director Incentive Award Plan, making 300,000 shares available for non-executive director equity compensation.","All 12 proposals passed, including director elections and advisory votes on executive compensation.","The 2025 Director Plan is successor to the 2015 Plan; no further awards under 2015 Plan.","Votes: ~93% approval for both plans; approximately 83.59% of shares represented at AGM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157179,"accession_number":"0001639691-25-000047","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Italian Ministry seeks €108.8M minimum costs in SNIA case; LivaNova disputes","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["On May 15, 2025, Italian Ministry served filing to Court of Appeal seeking minimum costs of approximately €108.8M, contrary to Supreme Court's decision that disapproved €157.3M.","LivaNova recorded €333.3M ($360.4M) current liability as best estimate for the SNIA environmental matter as of March 31, 2025.","Company disagrees with Ministry's assertions and intends to challenge them; no change to full-year 2025 guidance.","Italian Supreme Court referred case back to Court of Appeal for implementation regarding costs and damages per its judgment.","Ministry also requested a hearing in 2026 in connection with the proceedings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157178,"accession_number":"0001639691-25-000038","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LivaNova Q1: rev $316.9M (+10.4% organic); GAAP EPS -$6.01 (SNIA charge); adj EPS $0.88; FY25 adj EPS guide $3.60-$3.70","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $316.9M, +7.4% reported, +10.4% organic vs Q1 2024.","GAAP diluted loss per share $6.01 from €333.3M SNIA environmental liability ($360.4M).","Adjusted diluted EPS $0.88; adjusted free cash flow $20.0M.","FY25 constant-currency revenue growth guidance raised to 6-7%; organic 7-8%; adj EPS $3.60-$3.70.","Completed PMA submission for aura6000 System; OSPREY 12-month data showed strong response."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":316855000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175526,"accession_number":"0001639691-25-000014","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"LivaNova to record ~€333M liability after Italian Supreme Court ruling on SNIA environmental case","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Italian Supreme Court rules LivaNova jointly liable for SNIA environmental liabilities of €454M, but excludes €157M in prior payments.","Company expects to record a liability of ~€333M ($363M) in Q1 2025 as best estimate including costs, fees, interest, and taxes.","LivaNova has sufficient resources: cash $429M and restricted cash $295M as of Dec 31, 2024 to cover the liability.","Case remanded to Court of Appeal of Milan to implement decision on costs and damages."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175525,"accession_number":"0001639691-25-000008","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LivaNova Q4 revenue $321.8M (+6.8% organic); FY2025 adjusted EPS guidance $3.65-$3.75","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $321.8M (+6.8% organic YoY); GAAP EPS $1.02, adjusted EPS $0.81.","FY2024 revenue $1.25B (+10.7% organic); GAAP EPS $1.16, adjusted EPS $3.38.","FY2025 guidance: constant-currency revenue growth 5-6%, adjusted EPS $3.65-$3.75, adjusted FCF $135-155M.","OSPREY sleep apnea study met primary safety and efficacy endpoints at 6 months; RECOVER depression study publications support VNS Therapy.","Natalia Kozmina appointed Chief Human Resources Officer in January 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":1253437000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192480,"accession_number":"0001639691-24-000139","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CMS maintains VNS Therapy for DRE at Level 5 APC for 2025; LivaNova sees no business impact","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS announced on Nov 1, 2024 it will keep VNS Therapy for drug-resistant epilepsy at Level 5 Neurostimulator APC under the 2025 Medicare Hospital Outpatient PPS.","LivaNova says it is disappointed by the decision but does not expect any impact on its business.","The company plans to continue pursuing improved reimbursement for VNS Therapy for DRE."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192479,"accession_number":"0001639691-24-000129","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LivaNova Q3 revenue $318.1M (+11.2% YoY); raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $318.1M, up 11.2% reported and constant-currency; ex-ACS wind down, growth 12.3% constant-currency.","GAAP diluted EPS of $0.60; adjusted diluted EPS of $0.90.","Raised full-year 2024 guidance; company cites strong execution and momentum.","Board appointed Susan Podlogar in October 2024; serves on Compensation and Human Capital Management Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":931607000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192478,"accession_number":"0001639691-24-000125","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2024-10-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LivaNova appoints Susan Podlogar to board and compensation committee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appointed October 8, 2024 to Board and Compensation and Human Capital Management Committee.","Podlogar, 61, served as MetLife EVP/CHRO until June 2024 and 16 years at Johnson & Johnson.","Receives $60,000 annual retainer, $8,000 committee fee, and $180,000 RSU grant prorated for 2024.","No material transactions or arrangements between Podlogar and LivaNova since Jan 1, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208952,"accession_number":"0001639691-24-000117","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"LivaNova CHRO Trui Hebbelinck to depart Sept 30; search for successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Trui Hebbelinck will leave as Chief Human Resources Officer on Sept 30, 2024, then on garden leave until Sept 30, 2025.","She receives normal salary/benefits during garden leave, no 2025 bonus; equity awards continue vesting per terms.","Settlement includes prorated 2024 bonus at on-target, £232k severance, outplacement up to £20k, and tax/legal assistance.","Company retained an external search firm to find a new Chief Human Resources Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208951,"accession_number":"0001639691-24-000105","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LivaNova Q2 revenue $318.6M (+8.4%), adj. EPS $0.93; raises FY outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $318.6M, up 8.4% reported and 9.6% constant-currency; ex-ACS wind down, constant-currency growth 10.8%.","GAAP diluted EPS $0.30; adjusted diluted EPS $0.93.","Raised full-year 2024 revenue and adjusted diluted EPS guidance.","Franco Poletti named President of Cardiopulmonary Business Unit, effective August 1, 2024.","Plans to pursue CMS coverage for VNS Therapy in RECOVER patient population; reducing 2025 investment in difficult-to-treat depression."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":613487000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226772,"accession_number":"0001639691-24-000075","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"LivaNova shareholders approve equity plan share pool increases at 2024 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["A&R 2022 Plan options/SARs pool increased to 2,950,000 shares from 2,250,000; other awards to 2,000,000 from 1,500,000.","2015 Plan non-employee director pool raised to 150,000 shares from 50,000; plan expiration extended to June 2034.","All nine director nominees re-elected; advisory say-on-pay approved with ~95% of votes cast in favor.","Advisory vote on say-on-pay frequency set to annual; 22.2M votes for 1-year vs 5.1M abstentions and 20.5M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226771,"accession_number":"0001639691-24-000054","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LivaNova Q1 revenue $294.9M (+12% YoY); raises FY2024 guidance; OSPREY study positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $294.9M, up 12.0% reported, 12.4% constant-currency YoY; adjusted EPS $0.73 vs GAAP loss $0.78.","Cardiopulmonary and Neuromodulation each grew double-digit; ACS wind down on track for end-2024.","Raised full-year 2024 revenue and adjusted diluted EPS guidance (exact figures not in excerpt).","Positive predictive outcome in OSPREY obstructive sleep apnea study; enrollment completed.","Closed $345M 2.50% convertible notes due 2029; repurchased $230M exchangeable notes due 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":294912000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245736,"accession_number":"0001639691-24-000034","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"LivaNova issues $345M convertible notes, repurchases $230M of existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $345M aggregate principal of 2.50% convertible senior notes due 2029","Repurchased $230M of existing 3.00% Cash Exchangeable Senior Notes for ~$270.5M","Entered into capped call transactions covering shares underlying the notes","Amended credit agreement, increasing revolving facility from $125M to $225M"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245735,"accession_number":"0001639691-24-000031","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LivaNova prices $300M 2.5% convertible notes due 2029; plans to repurchase $230M of 3% exchangeable notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Priced $300M aggregate principal of 2.50% convertible senior notes due 2029; initial purchasers may buy up to $45M more.","Net proceeds estimated at ~$289.3M ($333M if over-allotment exercised); use includes repurchasing $230M of existing 3% notes.","Initial conversion price $69.40/share, a 32.5% premium to LIVN's $52.38 close on March 5, 2024.","Entered capped call transactions with cap price $94.284/share to offset dilution upon conversion.","Plans to repurchase $230M of 3.00% Cash Exchangeable Senior Notes due 2025 for $270.5M cash (incl. interest)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245734,"accession_number":"0001639691-24-000027","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LivaNova announces $300M convertible note offering due 2029, with $45M greenshoe","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Proposed $300M convertible senior notes due 2029; initial purchasers granted 13-day option for additional $45M.","Notes are senior unsecured, convertible upon conditions; interest rate and conversion rate to be determined at pricing.","Enters capped call transactions to offset dilution; also considering repurchasing some of its 3.00% exchangeable notes due 2025.","Net proceeds to fund capped calls, repurchases, and general corporate purposes; also negotiating credit facility amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245733,"accession_number":"0001639691-24-000016","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LivaNova Q4 revenue $310M (+12.8%), adj. EPS $0.87; full-year $1.15B; new CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $310.1M, up 12.8% reported (11.9% constant currency) vs prior year.","Q4 GAAP diluted EPS $0.30; adjusted diluted EPS $0.87.","Full-year 2023 revenue $1.15B, up 12.9% reported (13.3% constant currency).","Full-year GAAP diluted EPS $0.32; adjusted diluted EPS $2.80, up 17% YoY.","Board named Vladimir A. Makatsaria CEO effective March 1, 2024; winding down Advanced Circulatory Support segment."],"consensus_eps_estimate":null,"consensus_eps_actual":0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":1153545000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245732,"accession_number":"0001639691-24-000013","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"LivaNova appoints Vladimir Makatsaria as CEO effective March 1, 2024; Kozy remains Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Vladimir Makatsaria, former J&J MedTech Ethicon head, named CEO and Board member effective March 1, 2024.","Makatsaria receives annual base salary of $930,000, target bonus of 110% of base, and LTI grants totaling $6.85M.","Interim CEO William Kozy steps down as CEO on March 1 but continues as Board Chair.","Employment agreement includes sign-on cash bonus of $200,000 and relocation benefits from NYC to Houston.","Makatsaria holds BA in Physiology, MBA and MHA from University of Minnesota."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245731,"accession_number":"0001639691-24-000006","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.05","2.06","9.01"],"status":"ready","headline":"LivaNova approves restructuring plan, winds down ACS unit; expects ~$110M impairment in Q4 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved restructuring to focus on Cardiopulmonary and Neuromodulation; wind down ACS unit by end of 2024.","Pre-tax restructuring charges of $15M-$20M in 2024, including $10M-$12M severance/retention and $5M-$8M other expenses.","Triggering event in Q4 2023 leads to pre-tax non-cash impairment charge up to $110M, primarily for finite-lived intangibles.","Some ACS products transitioned to Cardiopulmonary; LifeSPARC and Hemolung systems to be discontinued by end of 2024.","Company to realign into two reportable segments: Cardiopulmonary and Neuromodulation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263201,"accession_number":"0001104659-23-125585","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2023-12-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"LivaNova updates on cyber incident: all manufacturing sites operating at normal levels","summary_kind":"llm","event_type":"cyber","confidence":"high","bullets":["All manufacturing sites worldwide substantially operating at normal levels as of Dec 13, 2023.","Company believes it has contained the cybersecurity threat; investigation and mitigation ongoing.","Full impact on business, results, cash flows, and financial condition still being assessed.","Initially disclosed cyber incident on Nov 20, 2023; took systems offline and engaged external experts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263200,"accession_number":"0001104659-23-123806","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2023-12-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"LivaNova reports progress on cybersecurity incident: US sites at normal levels, European sites starting soft launch","summary_kind":"llm","event_type":"cyber","confidence":"high","bullets":["On Dec 6-7, 2023, LivaNova executives discussed the cybersecurity incident at Mizuho and Wolfe investor meetings.","US manufacturing sites have successfully completed a soft launch and are now substantially operating at normal levels.","European manufacturing sites have begun a soft launch, but full normalization may take longer than US sites.","The incident was originally disclosed on November 20, 2023; the update covers operational recovery progress."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263199,"accession_number":"0001104659-23-119971","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2023-11-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"LivaNova detects cybersecurity incident; business disrupted, impact unknown","summary_kind":"llm","event_type":"cyber","confidence":"medium","bullets":["Company detected a cybersecurity incident disrupting IT systems; investigation with external experts and law enforcement underway.","Remediation measures include taking certain systems offline; business operations disrupted and expected to continue.","Company cannot yet determine the extent of the impact on business, results, cash flows, or financial condition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263198,"accession_number":"0001639691-23-000108","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LivaNova Q3 revenue $286M (+13.3% YoY); raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $286.1M, up 13.3% reported and 12.1% constant currency vs prior year.","GAAP diluted loss per share $0.14; adjusted diluted EPS $0.73.","Received FDA 510(k) clearance and CE Mark for Essenz In-Line Blood Monitor.","Raised full-year 2023 revenue and adjusted diluted EPS guidance.","Double-digit revenue growth across all regions and three business units."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":843413000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263197,"accession_number":"0001639691-23-000106","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2023-10-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LivaNova extends interim CEO Kozy's term; grants $750K RSU award","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board extends interim CEO William A. Kozy's term until earlier of successor CEO start or April 13, 2024.","Compensation Committee grants Kozy a one-time RSU award with $750,000 grant date fair value effective Dec 15, 2023.","RSUs vest upon earlier of successor CEO commencement or April 13, 2024, contingent on continued employment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263196,"accession_number":"0001639691-23-000093","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2023-10-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LivaNova appoints J. Christopher Barry to Board; Andrea Saia to retire Dec 31","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["J. Christopher Barry appointed to Board and Audit and Compliance Committee, effective Oct 6, 2023.","Barry is former CEO of NuVasive (until merger with Globus Medical in Sept 2023) and ex-SVP at Medtronic.","Barry will receive annual retainer of $110k, audit committee fee $15k, and $130k restricted stock award.","Andrea Saia notified retirement from Board effective Dec 31, 2023; no disagreement cited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280395,"accession_number":"0001639691-23-000087","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2023-09-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LivaNova Cardiopulmonary President Marco Dolci to retire Dec 31, 2023, receives €860,000","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Marco Dolci, President of the Cardiopulmonary business unit, announced retirement effective Dec 31, 2023.","Retirement settlement includes €860,000 payment under Italian law and continued vesting of unvested equity awards.","Mr. Dolci will remain in his role through the retirement date to support transition; he joined LivaNova in March 2017."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280393,"accession_number":"0001639691-23-000090","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K/A","filed_at":"2023-09-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LivaNova Cardiopulmonary President Marco Dolci to retire Dec 31, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Marco Dolci, President of the Cardiopulmonary Business Unit, announced retirement effective December 31, 2023.","Dolci will remain in role until his retirement date, focusing on transition of duties.","Retirement Settlement Agreement provides regular pay and benefits until retirement plus €860,000 lump sum under Italian law.","Unvested equity awards continue to vest per their terms; agreement includes mutual releases and waivers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280394,"accession_number":"0001639691-23-000070","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LivaNova Q2 revenue $294M (+16% CC); raises FY guidance; adjusted EPS $0.78","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $293.9M, up 15.6% reported and 16.4% constant currency YoY.","GAAP diluted EPS $0.02; adjusted diluted EPS $0.78.","Full-year 2023 guidance raised (specifics not detailed in excerpt).","Randomized 150th patient in RECOVER bipolar depression study; interim analyses begun.","Stephanie Bolton named President of Global Epilepsy effective May 12."],"consensus_eps_estimate":null,"consensus_eps_actual":0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":557300000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298944,"accession_number":"0001639691-23-000057","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"LivaNova shareholders approve amended 2022 incentive plan; increases share pool by 650,000","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved Amended & Restated 2022 Incentive Award Plan; options/SARs pool increased from 1,900,000 to 2,250,000 shares; other awards pool from 1,200,000 to 1,500,000 shares.","All nine director nominees elected; say-on-pay passed with 37,436,778 votes for, 3,095,082 against.","Ratification of PwC as independent auditor for 2023 passed with 43,883,022 votes for, 39,922 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298943,"accession_number":"0001639691-23-000043","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LivaNova Q1 revenue up 9.7% to $263M, EPS $0.14, raises 2023 guidance; names interim CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $263.4M, +9.7% reported (+12.7% constant currency) vs. prior year.","GAAP diluted EPS $0.14; adjusted diluted EPS $0.43.","Received FDA 510(k) clearance for Essenz heart-lung machine.","Randomized 500th unipolar depression patient in RECOVER study.","Bill Kozy appointed interim CEO after Damien McDonald's resignation; full-year 2023 guidance raised."],"consensus_eps_estimate":null,"consensus_eps_actual":0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":263418000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298942,"accession_number":"0001639691-23-000039","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2023-04-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LivaNova appoints William Kozy interim CEO with $975k salary, $500k RSU grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William A. Kozy, formerly Chair of Board, appointed interim CEO effective April 14, 2023.","Annual base salary of $975,000; target annual bonus of 110% of base salary, pro-rated.","One-time RSU award of $500,000 granted June 15, 2023, vesting at six-month anniversary.","Term continues until successor CEO or up to 6 months (extendable to 12 months by Board).","Kozy waives director fees and non-executive Chair equity awards during interim CEO tenure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298941,"accession_number":"0001639691-23-000037","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2023-04-14T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"LivaNova CEO Damien McDonald resigns; interim CEO William Kozy appointed; preliminary Q1 revenue $263M up 9%","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Damien McDonald resigned as CEO effective April 14, 2023; William Kozy appointed interim CEO.","Board retained executive search firm to identify permanent CEO; Kozy remains Board Chair.","McDonald receives £1,062,138.55 notice payment; unvested equity forfeited; garden leave until May 31, 2023.","Preliminary Q1 2023 revenue $263M, up 9% from $240M in Q1 2022.","Full first-quarter results will be released May 3, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319117,"accession_number":"0001639691-23-000025","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2023-03-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LivaNova completes enrollment of 500th unipolar patient in RECOVER depression trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Independent committee advised enrollment to continue from 475 to 500 unipolar patients per protocol.","500th unipolar patient randomized on March 23, 2023; final analysis after 12-month follow-up data.","Trial evaluates Vagus Nerve Stimulation for difficult-to-treat depression; results to be published."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319116,"accession_number":"0001639691-23-000010","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2023-02-22T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"LivaNova Q4 revenue up 6.2% constant currency; adjusted EPS $0.81","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $274.9M (+6.2% constant currency); GAAP EPS $0.03, adjusted EPS $0.81.","FY2022 revenue $1.02B (+2.9% constant currency); GAAP loss per share $1.61, adjusted EPS $2.39.","First clinical cases of Essenz perfusion system completed; LifeSPARC ECMO 510(k) cleared.","FDA Warning Letter for Munich facility and 3T Heater-Cooler closed out."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":1021805000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319115,"accession_number":"0001639691-23-000006","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2023-02-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LivaNova: RECOVER depression trial enrollment extended to 475 unipolar patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Independent Statistical Analysis Committee advises to continue enrollment from 450 to 475 unipolar patients.","Trial uses interim analyses every 25 patients; predictive probability of success not yet reached.","Successful trial could support reconsideration of CMS reimbursement for VNS Therapy for difficult-to-treat depression.","After last RCT patient completes 12-month follow-up, final analysis will be conducted on complete dataset."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319114,"accession_number":"0001639691-23-000003","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2023-01-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LivaNova RECOVER depression trial enrollment to continue to 450 patients per DSMB advice","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Independent Statistical Analysis Committee advised enrollment continue from 425 to 450 unipolar patients.","Trial remains on track; interim analyses every 25 patients assess predictive probability of success.","If successful, results could support peer-reviewed article and CMS reimbursement reconsideration for VNS Therapy.","No efficacy or safety signal disclosed; trial continues per protocol."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337344,"accession_number":"0001639691-22-000114","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2022-12-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LivaNova boosts CFO Alex Shvartsburg's base salary to £430k effective Jan 1, 2023","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Base salary increased from £360,000 to £430,000 (approx. 19% increase).","Increase includes accelerated 2023 merit adjustment and market calibration as CFO.","Approved by Compensation Committee on December 14, 2022, effective January 1, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337343,"accession_number":"0001639691-22-000112","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2022-12-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"LivaNova announces FDA Warning Letter closed for Munich and Arvada facilities","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued Warning Letter in Dec 2015 over regulatory violations at two facilities.","Company completed remediation actions to address alleged violations and observations.","Received FDA communication dated Nov 28, 2022 indicating the Warning Letter is closed.","No penalty or ongoing compliance obligations detailed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337342,"accession_number":"0001639691-22-000110","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2022-11-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LivaNova's RECOVER depression trial enrollment expanded to 425 unipolar patients after interim analysis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Independent Statistical Analysis Committee advised continuing enrollment to 425 unipolar patients, up from 400.","Interim analyses occur every 25 patients; cessation of RCT enrollment when predictive probability threshold met.","Final analysis after 12-month follow-up of last RCT patient; data to support CMS reimbursement reconsideration for VNS Therapy.","Company disclosed the update via Form 8-K on November 28, 2022, regarding event on November 23, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337341,"accession_number":"0001639691-22-000106","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2022-11-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Italian Supreme Court refers SNIA environmental liability question to ECJ, delaying final decision until at least 2024","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Italian Supreme Court referred question to ECJ on whether demerged company can be held liable for post-demerger environmental liabilities from pre-demerger actions.","Referral delays final decision on LivaNova's liability until at least 2024.","ECJ must provide binding interpretation before Supreme Court rules on appeals and counter-appeals.","Ministry of Ecological Transition, Ministry of Economy and Finance, and Prime Minister Office are counter-appellants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337340,"accession_number":"0001639691-22-000098","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LivaNova Reports Third-Quarter 2022 Results with Revenue of $252.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $252.6M decreased 0.2% reported but increased 5.2% on constant-currency basis vs prior year.","GAAP diluted loss per share of $2.01 includes non-cash goodwill impairment of ~$2.40 per share; adjusted diluted EPS was $0.58.","Michael Hutchinson named Senior Vice President, Chief Legal Officer and Company Secretary, succeeding Keyna Skeffington.","Full-year 2022 outlook unchanged; focus on core growth drivers, clinical pipeline, and cash generation."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":746931000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337339,"accession_number":"0001639691-22-000094","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2022-10-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LivaNova RECOVER depression trial enrollment continues from 375 to 400 unipolar patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Independent Statistical Analysis Committee advised continuation of RECOVER trial enrollment from 375 to 400 unipolar patients, per protocol.","Trial includes frequent interim analyses every 25 patients to assess predictive probability of success.","Upon meeting success criteria, RCT enrollment stops and patients enter open-label longitudinal study.","Final analysis after last RCT patient completes 12 months follow-up; data to support peer-reviewed article.","Success could lead to CMS reconsideration of reimbursement for VNS Therapy for difficult-to-treat depression."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354710,"accession_number":"0001639691-22-000088","cik":1639691,"company_name":"LivaNova PLC","ticker":"LIVN","form_type":"8-K","filed_at":"2022-09-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LivaNova appoints Brooke Story to Board of Directors effective Sept 15, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brooke Story appointed to LivaNova Board, brings over 20 years in medtech; currently Worldwide President at BD.","Story previously held leadership roles at Medtronic, including President of Pelvic Health and Gastric Therapies.","She will receive a prorated annual board retainer of $110,000, NG committee fee of $8,000, and $130,000 RSU grant.","No arrangement or related-party transactions exist between Story and LivaNova.","Story fills a board vacancy; compensation consistent with company's Remuneration Policy for non-employee directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3955489653.904938,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-09-15T23:59:59+00:00|354710"}